In Vivo Applications of Clone 3G8 in Mice

Clone 3G8 is a wellcharacterized monoclonal antibody that targets human CD16 (FcγRIII), a receptor primarily expressed on natural killer (NK) cells, neutrophils, monocytes, and macrophages. While 3G8 is highly specific for human and some nonhuman primate CD16, its direct crossreactivity with murine CD16 is limited, and thus, its typical in vivo uses are focused on humanized mouse models or applications involving human or primate CD16.

Functional Roles of 3G8

• Blockade of AntibodyDependent Cellular Cytotoxicity (ADCC): In humanized mouse models, 3G8 is used to block or modulate ADCC, which is mediated by CD16 on human immune cells present in the host mice. This is extremely valuable in studies evaluating the role of ADCC in therapeutic antibody efficacy or immune evasion mechanisms.
• Inhibition of Neutrophil Function: 3G8 can block neutrophil phagocytosis, providing a tool to dissect the contribution of neutrophils in inflammation, infection, or antibodymediated processes.
• Modulation of NK Cells: The antibody stimulates NK cell proliferation and can deplete or functionally alter NK cell populations in vivo, which is relevant for investigating tumor immunosurveillance, viral immunity, and autoimmune pathogenesis.
• Immune Cell Depletion/Signaling Studies: In some mouse models engrafted with human immune cells, 3G8 can be used to deplete specific immune populations or to study downstream signaling pathways triggered by CD16 engagement.

Key Considerations

• Species Specificity: 3G8 is effective on human and certain nonhuman primate CD16, but not on mouse CD16, so most in vivo applications require humanized or crossspecies models.
• Model Systems: Common uses include human peripheral blood mononuclear cell (PBMC)engrafted mice, hematopoietic stem cell (HSC)humanized mice, and xenograft models with human tumors and immune cells.
• Applications Beyond Blocking: Some vendors provide 3G8 in “in vivo grade” or “ultralow endotoxin” formulations, indicating suitability for systemic administration in animal models.

Summary Table: Applications of Clone 3G8 in Mice

Expert Notes

Clone 3G8 is a powerful tool for in vivo studies of human CD16 biology, but it is not a substitute for mousespecific CD16 antibodies in native mouse biology. Its value lies in humanized systems, where it enables precise manipulation of human immune cell function within a murine host. For native mouse studies, antimouse CD16/32 (FcγRIII/II) antibodies (e.g., 2.4G2) should be used instead.

Commonly used antibodies or proteins with 3G8 (antiCD16) in the literature include other antiCD16 clones (such as CB16, B73.1, MEM154) and antibodies targeting related Fc gamma receptors, notably antiFcγRIIa.

Key coreagents include:

• AntiCD16 clones: CB16, B73.1, MEM154
  These clones are often used in parallel with 3G8 to compare specificity, functional activation, and epitope binding on NK cells and other immune cells.
• AntiFcγRIIa (CD32) antibodies:
  3G8 is commonly paired with antiFcγRIIa antibodies in neutrophil activation or receptor cooperation studies, since FcγRIIIb (recognized by 3G8) and FcγRIIa function synergistically in cellular activation assays.
• CD107a antibody (degranulation marker):
  When assessing NK cell functional activity or expansion, researchers often include markers like CD107a, along with measurements of cytokines such as IFNγ and TNFα, to characterize responses induced by 3G8 and other clones.
• IgG and engineered antibodies:
  Studies using 3G8 may also employ protein reagents like recombinant IgG subclasses or Fcengineered antibodies to test binding and cellular activation via CD16.
• Other lymphocyte and myeloid markers:
  In multicolor flow cytometry panels, antibodies against markers such as CD3, CD20, CD14, CD56, and others are frequently combined with 3G8 to define and characterize cell populations expressing CD16.

These combinations enable detailed analysis of antibodydependent cellular cytotoxicity (ADCC), phagocytosis, cytokine secretion, and CD16 receptor biology in immunological studies.

The key findings from citations involving the clone 3G8 in scientific literature highlight several important functions and applications of this antiCD16 monoclonal antibody:

1. Cell Surface Binding and Activation:

   • Neutrophil Activation: Clone 3G8 interacts with FcγRIIa and FcγRIIIb receptors, leading to neutrophil activation and aggregation. This interaction can cause changes in the number of granulocytes or alter their scatter profile in whole blood assays.
   • Blocking Phagocytosis: It blocks phagocytosis, which is an essential function for immune cells like neutrophils and macrophages.

2. NK Cell Interactions:

   • NK Cell Proliferation: Clone 3G8 stimulates natural killer (NK) cell proliferation, which is crucial for immune responses against viral infections and tumor cells.
   • NK Cell Expansion Rate: Studies have shown that the NK cell expansion rate varies among different antiCD16 clones, with the CB16 clone being more effective for NK cell expansion compared to 3G8, B73.1, and MEM154.

3. Crossreactivity and Epitope Recognition:

   • Crossreactivity with NonHuman Primates: Clone 3G8 crossreacts with CD16 on nonhuman primates, making it useful for studies involving these species.
   • Epitope Recognition: The epitope recognized by 3G8 is located on the putative FG loop of the membraneproximal Iglike domain of CD16, which is distinct from the epitopes recognized by other clones like B73.1 and MEM154.

4. Applications in Research:

   • Flow Cytometry and Immunohistochemistry: Clone 3G8 is commonly used in flow cytometric analysis and immunohistochemical staining of acetonefixed frozen tissue sections.
   • Depletion Studies: It has been used for depleting NK cells in vivo, which helps in understanding their role in immune responses.

The dosing regimens of clone 3G8, an antihuman CD16 monoclonal antibody, vary significantly across different mouse models depending on the experimental context and the type of humanization employed. The key factors influencing dosing include the mouse strain's immune tolerance to human antibodies and the duration of treatment required.

Standard Dosing Considerations

For flow cytometry applications in mouse models, clone 3G8 is typically used at concentrations of 10μl of a 0.5 mg/ml solution to label 1×10⁶ cells in 100μl, or at dilutions ranging from neat to 1/5. However, in vivo dosing regimens present more complex challenges related to antibody clearance and immunogenicity.

Humanized Mouse Models and Chronic Dosing

The most significant variation in dosing regimens relates to the mouse model's tolerance of human antibodies. In standard wildtype mouse strains such as C57BL/6, repeated administration of human antibodies like 3G8 leads to rapid clearance after 23 weeks of treatment due to the development of mouse antihuman antibody responses. When wildtype mice were dosed weekly with 100 μg of a fully human IgG1 antibody, they rapidly cleared the antibody to levels at or below the detection limit by day 35.

In contrast, human IgG1 knockin mouse models demonstrate dramatically improved tolerance for chronic human antibody administration. These mice maintain high serum levels of human antibodies even after five cycles of weekly 100 μg doses, as they do not mount an antihuman antibody response. This model enables longterm, repeated administration protocols that would be impossible in conventional mice.

ApplicationSpecific Dosing Variations

The dosing regimen also depends heavily on the experimental application. While specific in vivo dosing protocols for 3G8 itself are not extensively detailed in the search results, similar antibodies targeting cell surface markers in mouse models typically use doses ranging from 50300 μg per mouse for immune cell depletion or activation studies, administered via intraperitoneal or intravenous injection.

For chronic studies requiring repeated dosing, humanized FcγR mouse models provide additional advantages by allowing investigation of antibodydependent cellular cytotoxicity and other Fcmediated effector functions without the confounding variable of rapid antibody clearance. The choice between singledose versus multidose regimens must account for whether the mouse strain can maintain therapeutic antibody levels throughout the study period.